MDT
100.71
0%↓
A
135.72
-0.01%↓
VEEV
217.61
-2.73%↓
HQY
82.76
-2.65%↓
NEOG
10.24
+2.4%↑
MDT
100.71
0%↓
A
135.72
-0.01%↓
VEEV
217.61
-2.73%↓
HQY
82.76
-2.65%↓
NEOG
10.24
+2.4%↑
MDT
100.71
0%↓
A
135.72
-0.01%↓
VEEV
217.61
-2.73%↓
HQY
82.76
-2.65%↓
NEOG
10.24
+2.4%↑
MDT
100.71
0%↓
A
135.72
-0.01%↓
VEEV
217.61
-2.73%↓
HQY
82.76
-2.65%↓
NEOG
10.24
+2.4%↑
MDT
100.71
0%↓
A
135.72
-0.01%↓
VEEV
217.61
-2.73%↓
HQY
82.76
-2.65%↓
NEOG
10.24
+2.4%↑
24h
Corrente
Minimo
6.46
Massimo
7.12
Entrata | 4.1M -33M |
|---|---|
Vendite | 6.1M 44M |
EPS | -3.82 |
Margine di Profitto | -75.213 |
Dipendenti | 279 |
EBITDA | 1.8M -23M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +125.56% upside |
Capitalizzazione di Mercato | 20M 122M |
|---|---|
Apertura precedente | -0.03 |
Chiusura precedente | 7.08 |
By Acuity
50%
50%
148 / 352 Classifica in Healthcare
By Trading Central
Fiducia
Bullish Evidence
5.9501 / 7.66 Supporto e resistenza
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
27 gen 2026, 23:07 UTC
Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update
DJ
LeggI
27 gen 2026, 21:27 UTC
Texas Instruments 4Q Sales Rise, Profit Falls
DJ
LeggI
27 gen 2026, 23:55 UTC
Yen Weakens Slightly on Possible Technical Correction -- Market Talk
DJ
LeggI
27 gen 2026, 23:47 UTC
Global Forex and Fixed Income Roundup: Market Talk
DJ
LeggI
27 gen 2026, 23:47 UTC
Nikkei May Decline Amid Caution Over Earnings -- Market Talk
DJ
LeggI
27 gen 2026, 23:39 UTC
Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk
DJ
LeggI
27 gen 2026, 23:20 UTC
SK Innovation: Asset-Impairment Losses Weighed on Earnings
DJ
LeggI
27 gen 2026, 23:20 UTC
SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings
DJ
LeggI
27 gen 2026, 23:19 UTC
SK Innovation Posts Net Loss for Second Consecutive Year
DJ
LeggI
27 gen 2026, 23:19 UTC
SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE
DJ
LeggI
27 gen 2026, 23:18 UTC
SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE
DJ
LeggI
27 gen 2026, 23:18 UTC
SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE
DJ
LeggI
27 gen 2026, 23:11 UTC
Global Equities Roundup: Market Talk
DJ
LeggI
27 gen 2026, 23:11 UTC
Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk
DJ
LeggI
27 gen 2026, 23:07 UTC
Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk
DJ
LeggI
27 gen 2026, 22:17 UTC
U.S. Dollar Slips Following Trump Comments -- Market Talk
DJ
LeggI
27 gen 2026, 22:06 UTC
Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update
DJ
LeggI
27 gen 2026, 21:51 UTC
Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com
DJ
LeggI
27 gen 2026, 21:50 UTC
Basic Materials Roundup: Market Talk
DJ
LeggI
27 gen 2026, 21:43 UTC
RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com
DJ
LeggI
27 gen 2026, 21:41 UTC
GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update
DJ
LeggI
27 gen 2026, 21:38 UTC
These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com
DJ
LeggI
27 gen 2026, 21:32 UTC
Ampol: Modest Profit From F&I International in 2025
DJ
LeggI
27 gen 2026, 21:32 UTC
Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025
DJ
LeggI
27 gen 2026, 21:31 UTC
Ampol: New Zealand Ebit in 2025 In Line With Prior Year
DJ
LeggI
27 gen 2026, 21:31 UTC
Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025
DJ
LeggI
27 gen 2026, 21:30 UTC
Ampol 4Q Lytton Refinery Production 1.56 Billion Liters
DJ
LeggI
27 gen 2026, 21:29 UTC
Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion
DJ
LeggI
27 gen 2026, 21:29 UTC
Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million
DJ
LeggI
27 gen 2026, 21:28 UTC
Ampol 4Q Lytton Refiner Margin US$15.14/Bbl
DJ
LeggI
Modifica del prezzo
By TipRanks
Previsioni per 12 mesi
Media 15 USD 125.56%
Alto 23 USD
Basso 10 USD
Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Karyopharm Therapeutics Inc - Dist negli ultimi 3 mesi.
By TipRanks
Fortemente da comprare
4 ratings
4
Acquista
0
Mantieni
0
Vendi
Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Karyopharm Therapeutics Inc - Dist negli ultimi 3 mesi.
By Trading Central
A breve termine
Bullish Evidence
Recent bullish events outweigh bearish events.
A termine intermedio
Strong Bearish Evidence
All events are bearish.
A lungo termine
No Evidence
There are no events.
By Acuity
Notizie sul Sentiment di mercato
Neutral
Volatilità
Sotto la media
Volume delle notizie (RCV)
Sotto la media
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$